TriVascular Technologies — Merger or Acquisition (January 2016)
21 slides from TriVascular Technologies's merger presentation, Jan 12, 2016
Slide 1: Combining innovation leaders to revolutionize aortic treatments
Combining innovation leaders to revolutionize aortic treatments January 2016 Filed by Endologix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: TriVascular Technologies, Inc. Commission File
Slide 2: Safe Harbor
Safe Harbor Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. Forward-Looking Statements This presentation includes
Slide 3: Building the Leading Global Innovator of Aortic Therapies
Building the Leading Global Innovator of Aortic Therapies Unmatched Technology: EVAR + EVAS Innovation leader w/ broadest product offering Industry leading clinical evidence Robust and Sustainable Growth: 20% CAGR through 2020 & beyond ~200 person sales force + distribution network Multiple product
Slide 4: Building the Leading Global Innovator of Aortic Therapies
Building the Leading Global Innovator of Aortic Therapies Unmatched Technology: EVAR + EVAS Robust Growth: 20% CAGR through 2020 Accelerated Path to Profitability: EBITDA accretive by 2018
Slide 5: Only Company with Both EVAR and EVAS Solutions
EVAR Only Company with Both EVAR and EVAS Solutions Proximal fixation Ultra-low profile Polymer sealing ring Highly flexible Anatomical Fixation Preserve bifurcation Infra/suprarenal EVAS AAA fixation Complete polymer sealing Infrarenal + ChEVAS Lowest endoleaks Combined ELGX and TRIV portfolio TriV
Slide 6: Broadest Patient Applicability
Broadest Patient Applicability % Patients within FDA IFU* *Based on FDA Labeled Neck Indications for infrarenal devices Derived from M2S Database of 43,000 AAA CT Scans Represents treatment applicability post merger with AFX, Ovation and Nellix (all CE marked)
Slide 7: Significant Clinical Evidence To Drive Adoption
Significant Clinical Evidence To Drive Adoption 2016 2017 2016 2017 2016 2017 4,300+ Patients Enrolled by 2017 IDE/CAP/PAS Global Registry LIFE LUCY TriVascular OVATION 4 years IDEs PEVAR LEOPARD Endologix AFX 7+ years Global Registry IDE/CAP Complex Endologix NELLIX 1 year Years of follow-up
Slide 8: Proven ability to treat a broad range of patients
Proven ability to treat a broad range of patients First ever prospective, all-comers EVAS study EVAS FORWARD Global Registry 1 year 0.7% overall endoleak rate at 1 year follow up Endoleak 1.4% aneurysm-related mortality ARM 300 patients 30 sites Nellix Clinical Results 37% patients off-IFU Anatomy 5
Slide 9: Key Milestones to Nellix US Approval
Key Milestones to Nellix US Approval* Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar 2016 2017 Presentation of 1 year IDE clinical data *Based upon current timelines and assumptions PMA Module 2 PMA Approval* FDA Review PMA Module 4
Slide 10: Building the Leading Global Innovator of Aortic Therapies
Building the Leading Global Innovator of Aortic Therapies Unmatched Technology: EVAR + EVAS Robust Growth: 20% CAGR through 2020 Accelerated Path to Profitability: EBITDA accretive by 2018
Slide 11: $4.7B Aortic Aneurysm Market Opportunity
$4.7B Aortic Aneurysm Market Opportunity TAA Opportunity Treated – 49% Complex AAA Opportunity Treated – 28% Traditional AAA Opportunity Treated – 78% $4.7B $ Billions CAGR 5% CAGR 4% CAGR 9%
Slide 12: 2016 Salesforce Milestones
2016 Salesforce Milestones 1Q 2016 2Q 2016 3Q 2016 4Q 2016 Deal Close Train and Launch Ovation iX in U.S. and EU Train and Launch Nellix in EU Train and Launch AFX2 in U.S. Cross-selling Train and Launch AFX2 in EU Train for Nellix Launch Following PMA Approval ~200 experienced aortic specialists an
Slide 13: Product Platforms = Competitive Advantage
3 Product Platforms = Competitive Advantage Proximal Fixation Anatomical Fixation Aneurysm Sealing EVAR EVAS Competition Only Company providing physicians and hospitals with multiple device solutions for each patient
Slide 14: Best Positioned to Capture Complex EVAR Market Opportunity
Juxtarenal <5mm Best Positioned to Capture Complex EVAR Market Opportunity Short Neck Infrarenal 5mm – 10mm Suprarenal Type IV AAA No neck 2020 Complex AAA Market: $1.5 Billion NELLIX CHEVAS OVATION ALTO
Slide 15: Robust New Product Pipeline
U.S. Europe Asia Pacific Latin America Robust New Product Pipeline* 2015 2016 2017 2018 2019 2020 (Japan) (China) (Japan) (Brazil) (Argentina) (Japan) (Brazil, Argentina) CHEVAS CHEVAS CHEVAS THORACIC * Post-merger estimated regulatory approvals CHEVAS
Slide 16: Building the Leading Global Innovator of Aortic Therapies
Building the Leading Global Innovator of Aortic Therapies Unmatched Technology: EVAR + EVAS Accelerated Path to Profitability: EBITDA accretive by 2018 Robust Growth: 20% CAGR through 2020
Slide 17: Forecasted Merger Synergies
Forecasted Merger Synergies Public Co Support function overlap R&D leverage Vertical integration Facility leverage Sales & Marketing synergies * Excludes the impact of TRIV PPA Clear visibility to forecasted synergies Programs to drive vertical integration … PTFE, Polymer, Insourcing Shared Service
Slide 18: Integration: Top Priorities
Integration: Top Priorities Providing the most comprehensive AAA product line on the path to profitability Optimize Sales Force Cross training Distributor transitions New product launches Minimize Disruption Dedicated integration teams Isolate key programs (nellix) Experienced executive team Success
Slide 19: Forecasting Significant Growth and Leverage
Forecasting Significant Growth and Leverage ELGX 2015 TRIV 2015(3) Combined 2015 Fcst ELGX 2020 Fcst Comments Sales $154-$157M $36-39M $190-$196M $425-$480M 20% CAGR(2) Gross Margin %(1) 68% 62% 67% 74% +7 pts R&D % ~25% ~50% ~30% ~12% Investing at industry Standards SG&A % ~70% ~150%+ ~85% ~40% Sal
Slide 20: Summary
Summary Most Comprehensive AAA Product Line est device for each patient Market expanding new product pipeline Traditional AAAs, Complex AAAs and Thoracic ~30% Larger Global Sales Force Significant Clinical Evidence Over 4,300 patients in 2017 Top Tier Forecasted Financial Performance: Revenue CAGR o
Slide 21: Treat more patients more effectively
Treat more patients more effectively
TriVascular Technologies — Merger or Acquisition (January 2016) on 6ix